Gene therapy developer Jaguar has completed a series B round co-led by Eli Lilly and Deerfield Management.
Pharmaceutical firm Eli Lilly co-led a $139m series B round for US-based gene therapy developer Jaguar Gene Therapy yesterday with healthcare investment firm Deerfield Management.
Investment banking firm Goldman Sachs also took part in the round, along with venture capital firm Arch Venture Partners and Nolan Capital, the family office for Jaguar chairman Sean P. Nolan.
Jaguar is working on gene therapies for a metabolic disorder known as galactosemia as well as for type 1 diabetes and a specific genetic…
